Latest Regulatory Filings News

5E Advanced Materials has announced a significant upgrade to its Fort Cady Project, increasing measured and indicated borate resources by 61% and lithium resources by 54%, positioning it as a leading domestic supplier of critical minerals.

AFT Pharmaceuticals delivered a robust first half for FY26, posting 33% revenue growth and a return to profitability, driven by strong Australian sales and recovery in Asia and international markets. The company is advancing its global footprint and R&D pipeline, positioning for sustained growth.

The Supreme Court of Western Australia has approved the share and option schemes for Capricorn Metals’ acquisition of Warriedar Resources, setting the stage for a significant consolidation in the gold exploration sector.

DroneShield Limited has clarified the recent sharp decline in its share price, attributing the market movement to disclosed director share disposals rather than any undisclosed material information.

Anteris Technologies has gained FDA approval to start patient recruitment in the US for its pivotal PARADIGM Trial, following initial European regulatory success. The company advances manufacturing and clinical readiness as it pushes toward key regulatory milestones.

Coronado Global Resources posted a $109.5 million net loss for Q3 2025 amid subdued metallurgical coal markets and announced a proposed refinancing deal with Stanwell Corporation to strengthen its financial position.

Optiscan Imaging has entered a three-year strategic collaboration with Australian Clinical Labs to validate and deploy its InForm™ digital pathology platform, aiming to transform diagnostic workflows with real-time tissue analysis.

ALS Limited has responded to an ASX inquiry regarding the delayed lodgement of key disclosure documents related to performance rights granted to director Malcolm Deane, attributing the delay to human error and outlining steps to reinforce compliance.

ReNerve Limited is scaling up its clinical trial for the NervAlign® Nerve Cuff following promising interim results that show significant pain reduction in nerve repair patients. The expanded study aims to solidify evidence for broader regulatory approval and market adoption.

Savannah Goldfields Limited has explained the late filing of a director’s interest notice, attributing it to an oversight during an entitlement offer. The company affirms its compliance processes remain robust despite the delay.

Merino & Co. initiates a new chapter with leadership changes and a strategic partnership to enter China’s premium apparel market, while investing heavily in growth during Q1 FY26.

Avecho Biotechnology advances its pivotal Phase III CBD insomnia trial with 160 patients dosed and secures $2.5 million to accelerate manufacturing and regulatory efforts ahead of a 2026 interim analysis.